Walk in interview in Quality Control, Production at Dr. Reddy's Laboratories
Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection.
This is a question we’ve asked ourselves over and over. It’s how we at Medtronic have made hearts beat stronger and longer. It’s how we’ve pushed the limits of what technology can do in and for the body. It’s how we will continue to alleviate pain, restore health and extend life. Rising costs, an aging population, and the burden of chronic disease impact us all. And no single entity in the healthcare system can solve these challenges alone. That’s why we’re stepping forward. That’s why we’re prepared to put the full power of our technologies, services, resources — and our people — to work with new partners, in new ways, to usher in a new era in healthcare.
Sava Healthcare Limited is part of Sava Group, which is esteemed 2003 and headquartered in Pune, India, is an integrated PIC/s and WHO-GMP certified manufacturer and Exporter of one of the widest range of therapeutic products from solid/liquid/external preparation dosage forms.
Indian Council of Forestry Research and Education (ICFRE), an apex body in the national forestry research system, has been undertaking the holistic development of forestry research through need based planning, promoting, conducting and coordinating research, education and extension covering all aspects of forestry. The Council deals with the solution based forestry research in tune with the emerging issues in the sector, including global concerns such as climate change, conservation of biological diversity, combating desertification and sustainable management and development of resources. Topical research by the Council enhances public confidence in the ability of forest managers and researchers to successfully handle challenges related to natural resource management.
The history of Jamia Hamdard begins with the establishment of a small Unani clinic in the year 1906 by Hakeem Hafiz Abdul Majeed, one of the well-known practitioners of Unani System of Medicine of his time. Hakeem Hafiz Abdul Majeed had a vision of making the practice of Unani Medicine into a scientific discipline so that Unani medicines could be dispensed in a more efficacious manner to patients.
A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.
Cerner is a place where people are encouraged to innovate with confidence and focus on what is important – people’s health and the care they receive. We are transforming health care by developing tools and technologies that make it more efficient for care providers and patients to navigate the complexity of our health. From single offices to entire countries, Cerner solutions are licensed at more than 25,000 facilities in over 35 countries.
The Institute for Stem Cell Biology and Regenerative Medicine (inStem), is a state-of-the-art research institute in Bangalore, India, dedicated to the study of stem cell and regenerative biology. An autonomous institute funded by the Dept of Biotechnology, Govt. of India, inStem emphasizes collaborative research in stem cell biology. inStem’s mandate to allow this cross-disciplinary, multi-pronged approach to research, straddles the divide between clinical and laboratory research in stem cell biology. In trying to answer intractable and challenging questions that face the field, inStem seeks to rewrite the paradigm of the research institute: without barriers and across disciplines.
Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $3.9 billion in fiscal year 2009 (year ending March 31, 2010).
